PharmaEssentia Competitors and Similar CompaniesClear all
PharmaEssentia's competitors and similar companies include Tanvex BioPharma, Nektar Therapeutics, Takeda and Halozyme Therapeutics.
 PharmaEssentia PharmaEssentia (藥華醫藥股份有限公司) is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases. |  Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. | ||
Founding Date | Founding Date 2003 | Founding Date 2013 | Founding Date 1990 | Founding Date 1781 | Founding Date 1998 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Taipei, TW HQ Shinjuku City, JP Burlington, US | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations San Francisco, US HQ Hyderabad, IN Huntsville, US | Locations San Diego, US HQ | |
Employees | Employees 4897% increase | Employees 13827% decrease | Employees 61821% increase | Employees 47,4554% decrease | Employees 373157% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 233.8 m | Valuation ($) 43.7 b | Valuation ($) 6.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$15.6b (FY, 2025) | Revenue (est.) NT$401m (FY, 2025) | Revenue (est.) $55.2m (FY, 2025) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) $1.4b (FY, 2025) |
Cost of goods | Cost of goods NT$1.3b (FY, 2025) | Cost of goods NT$466.3m (FY, 2025) | Cost of goods N/A | Cost of goods ¥818.8b (FY, 2025) | Cost of goods $228.8m (FY, 2025) |
Gross profit | Gross profit NT$14.4b (FY, 2025) | Gross profit (NT$10.6m) (FY, 2025) | Gross profit N/A | Gross profit ¥3.8t (FY, 2025) | Gross profit $1.2b (FY, 2025) |
Net income | Net income NT$5b (FY, 2025) | Net income (NT$1.5b) (FY, 2025) | Net income ($164.1m) (FY, 2025) | Net income ¥108.1b (FY, 2025) | Net income $316.9m (FY, 2025) |
Operating ⚠ | |||||
Filed Trials Products | Filed Trials Products N/A | Filed Trials Products N/A | Filed Trials Products N/A | Filed Trials Products 16 (May, 2025) | Filed Trials Products 2 (FY, 2019) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products 10 (FY, 2020) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products 1 (FY, 2020) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products 8 (FY, 2020) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 346.9m | Total funding raised $ 45m | Total funding raised $ 57.8m | Total funding raised $ 171.9m |
For sources of this data, please see the company profile
View Company Profiles
Tanvex BioPharma
HQ
Taipei, TW
Employees
138↓ 27% decrease
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View company
Nektar Therapeutics
HQ
San Francisco, US
Employees
618↑ 21% increase
Nektar Therapeutics is a stage-clinical biopharmaceutical company.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View company